Summit Therapeutics 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   123 Trials   551 News 
119 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
NCT06930573: A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

Recruiting
4
30
RoW
AK112
The First Affiliated Hospital of Zhengzhou University
HCC
05/26
12/27
AK112-RWS-IIT, ChiCTR2500096483: Real-world clinical studies of Ivonescimab in locally advanced or metastatic non-squamous NSCLC with EGFR-TKI treatment failure

Recruiting
4
30
 
Higher Education Mega Center Hospital of Guangdong Provincial Hospital of Chinese Medicine; Higher Education Mega Center Hospital of Guangdong Provincial Hospital of Chinese Medicine
Lung cancer
 
 
HARMONi, NCT06396065: Phase III Study of AK112 for NSCLC Patients

Active, not recruiting
3
420
Europe, Canada, US
AK112 Injection, Pemetrexed, Carboplatin, Placebo Injection
Summit Therapeutics, Akeso
Non-Squamous Non-small Cell Lung Cancer
12/25
12/25
HARMONi-2, NCT05499390: AK112 in Advanced Non-Small Cell Lung Cancer

Active, not recruiting
3
398
RoW
AK112, Pembrolizumab
Akeso
Advanced Non-small-cell Lung Cancer
01/24
12/25
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Not yet recruiting
3
682
RoW
AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin
Akeso
Biliary Tract Cancer
07/27
12/27
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
3
510
RoW
AK117 in combination with AK112, Placebo in combination with Pembrolizumab
Akeso
Head and Neck Squamous Cell Carcinoma
01/27
10/27
HARMONi-6, NCT05840016: AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Active, not recruiting
3
532
RoW
AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel
Akeso
Advanced Squamous Non Small Cell Lung Cancer
02/25
12/26
HARMONi-A, NCT05184712: Phase 3 Clinical Study of AK112 for NSCLC Patients

Active, not recruiting
3
322
RoW
Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection
Akeso, Akeso
Non-Squamous Non-small Cell Lung Cancer
06/24
11/25
HARMONi-BC1, NCT06767527: AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Not yet recruiting
3
416
RoW
AK112, Nab-paclitaxel, Placebo
Akeso
Triple-Negative Breast Cancer (TNBC)
12/26
12/28
HARMONi-7, NCT06767514: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Recruiting
3
780
US
Ivonescimab Injection, Pembrolizumab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
04/28
06/29
NCT06951503: A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Not yet recruiting
3
560
RoW
AK112, Oxaliplatin, Irinotecan, Leucovorin and 5-FU, Bevacizumab
Akeso
Colorectal Adenocarcinoma
01/27
01/29
NCT06953999: A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer

Not yet recruiting
3
999
RoW
Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine, Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine, Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine
Akeso
Pancreatic Cancer
05/27
05/28
AK112-311, NCT07010263: A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Not yet recruiting
3
480
RoW
AK112, Ivonescimab, Placebo
Akeso
Small Cell Lung Cancer
12/28
07/29
AK112-305, NCT06928389: Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Not yet recruiting
3
536
NA
Ivonescimab, docetaxel, AK112, docetaxel, Placebo, docetaxel
Akeso
Non-Small Cell Lung Cancer
05/27
06/30
HARMONi-3, NCT05899608: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting
3
1080
Europe, Canada, Japan, US, RoW
Ivonescimab Injection, Pembrolizumab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
12/27
12/28
ChiCTR2500102884: A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112（PD-1/VEGF Bispecific Antibody）Versus Placebo as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Not yet recruiting
3
480
 
AK112 injection placebo; AK112 Injection
Jilin Cancer Hospital; Jilin Cancer Hospital, Akeso-Sino Pharma Co., Ltd.
Limited-stage small cell lung cancer without progression after standard concurrent chemoradiotherapy
 
 
AK112-206, NCT05382442: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Recruiting
2
254
US, RoW
AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil
Akeso, Summit Therapeutics
Metastatic Colorectal Cancer
05/26
08/28
AK117-203, NCT05227664: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Recruiting
2
120
RoW
AK117, AK112, Nab paclitaxel, paclitaxel
Akeso
Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer
07/25
12/26
AK112-203, NCT04870177: Study of AK112 in the Treatment of Advanced Gynecological Tumors

Completed
2
53
RoW
AK112
Akeso
Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm, Endometrial Neoplasms
05/24
05/24
AK112-207, NCT05432492: A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Not yet recruiting
2
60
NA
AK112
Akeso
Hepatocellular Carcinoma
08/23
08/24
AK112-205, NCT05247684: AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Not yet recruiting
2
30
NA
AK112, Carboplatin, Cisplatin, Paclitaxel
Akeso
Resectable Non-small Cell Lung Cancer
08/23
01/25
AK104-IIT-042, NCT06196775: A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2
36
RoW
AK104+AK112
Harbin Medical University
Hepatocellular Carcinoma
01/26
01/27
AK112-201, NCT04736823: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

Recruiting
2
296
RoW
AK112, Pemetrexed, Paclitaxel, Carboplatin, Docetaxel
Akeso
NSCLC
07/25
12/26
NCT06375486: Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Recruiting
2
30
RoW
Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, HAIC
Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma
03/25
06/26
AK104-IIT-041, NCT06196697: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Recruiting
2
50
RoW
Cadonilimab, AK104, Ivonescimab, AK112, XELOX, oxaliplatin and capecitabine, SOX, oxaliplatin and Tegafur
Harbin Medical University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/27
03/27
NCT06391008: Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Not yet recruiting
2
44
NA
Stereotactic radiotherapy, Evoximab, AK112, Pemetrexed, Albumin Paclitaxel, Carboplatin
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
12/24
06/25
AK112-IIT-C-W-0001, NCT06444009: A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
2
90
RoW
Ivonescimab combined with TP, ITP, Cadonilimab combined with TP, CTP, Penpulimab combined with TP, PTP
Lei Liu
Head and Neck Squamous Cell Carcinoma
12/25
12/27
AK112-IIT-004, NCT06491472: Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Recruiting
2
36
RoW
Ivonescimab, AK112/SMT112, Gemcitabine, Nab paclitaxel, SBRT
Wuhan Union Hospital, China, Akesobio
Pancreatic Cancer
07/26
07/27
NCT06537011: AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
36
NA
AK112
Wuhan Union Hospital, China
Neoadjuvant Therapy of Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
07/27
07/28
NCT06637007: Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

Recruiting
2
30
RoW
Chidamide Tablets combined with AK112, AK112
Shanxi Province Cancer Hospital
Sarcoma,Soft Tissue, Sarcoma, Sarcoma of Bone
12/24
12/24
NCT06478043: A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

Not yet recruiting
2
54
RoW
ivonescimab, AK112, irinotecan liposome, Irinotecan liposome injection
Zhejiang Cancer Hospital
Extensive-stage Small-cell Lung Cancer
09/25
09/27
NCT06620796: A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer

Not yet recruiting
2
70
NA
Arm 1, AK112+AK104 group, second-line group, AK112+AK104+paclitaxel
Shanghai Pulmonary Hospital, Shanghai, China
SCLC, Extensive Stage
09/26
09/27
NCT06802666: Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Recruiting
2
45
RoW
short-course radiotherapy, SCRT, Ivonescimab, AK112, capecitabine, oxaliplatin, TME surgery
Wuhan Union Hospital, China
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
09/26
12/27
Miracle-03, NCT06593548: Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer

Not yet recruiting
2
36
RoW
Ivosidenib (AK112)
Fudan University
CRC, MSS, Metastatic Cancer
11/26
11/26
NCT06684873: A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)

Not yet recruiting
2
55
RoW
AK112 Injection
Sun Yat-sen University
NSCLC, Brain Metastasases
12/27
12/27
AK104-221, NCT06560112: An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Recruiting
2
172
RoW
AK104, Cadonilimab, AK112, Ivonescimab, Chemotherapy, Monotherapy Non-Platinum Chemotherapy chosen by the investigator
Akeso
Recurrent Ovarian Cancer
05/26
05/27
AK112-IIT-009, NCT06489197: AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

Recruiting
2
30
RoW
Ivonescimab combined with albumin paclitaxel and cisplatin
Tianjin Medical University Cancer Institute and Hospital
ESCC, Advanced Esophageal Squamous Cell Carcinoma
10/26
08/27
NCT06683846: Ivocizumab in the Treatment of Multiple Advanced Tumors

Recruiting
2
400
RoW
Ivocizumab
Fudan University
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular Epithelioid Cell Tumor, Malignant, Sarcoma, Urachal Cancer, Neuroendocrine Cancer, Basal Cell Carcinomas, Sarcomatoid Carcinoma, Penile Cancer, Adrenal Cortical Cancer, Germ Cell Cancer Metastatic, Non-Clear Cell Renal Cell Carcinoma, Prostate Cancers, Clear Cell Renal Cancer, Urothelial Carcinoma, Kidney Cancer, Rare Tumors
11/27
11/27
NCT06402435: SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer

Recruiting
2
50
RoW
Lvonescimab (AK112)
Hubei Cancer Hospital
Breast Cancer
08/26
09/27
NCT06401005: SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

Recruiting
2
51
RoW
Cadonilimab (AK104)
Hubei Cancer Hospital
Breast Cancer
08/26
09/27
NCT06567314: Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

Recruiting
2
24
US
Ivonescimab
M.D. Anderson Cancer Center, Summit Therapeutics
Cutaneous Squamous Cell Carcinoma
09/28
09/30
BALISTA, NCT06793332: BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

Recruiting
2
39
RoW
Ivonescimab Combined With TROP2 ADC, AK112 Combined With TROP2 ADC
Fudan University
Triple-Negative Breast Cancer (TNBC), Brain Metastases
01/26
01/27
iTHYM, NCT06750952: Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial

Not yet recruiting
2
24
NA
Ivonescimab Combined With Chemotherapy, AK112
Sun Yat-sen University
Relapsed or Metastatic Thymic Cancer, First-line Treatment
12/26
12/28
NCT06760520: Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer

Not yet recruiting
2
40
NA
Ivonescimab (SMT112 or AK112) Injection
The First Affiliated Hospital of Zhengzhou University
Locally Advanced Rectal Cancer
12/27
12/31
HX-AK112-01, NCT06769295: A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

Recruiting
2
28
RoW
AK112, Pemetrexed, Carboplatin/Cisplatin
Sichuan University
Lung Cancer, Non-Small Cell
12/26
12/27
HX-AK112-02, NCT06769971: Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Recruiting
2
80
RoW
Ivonescimab, Cadonilimab, Etoposide, Carboplatin
Sichuan University
Small Cell Lung Cancer
12/26
12/27
NCT06814067: Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
80
RoW
Pembrolizumab, Ivonescimab, Surgery, Adjuvant radiotherapy
Fudan University, Fujian Cancer Hospital
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
02/29
03/30
TRIUNITE-03, NCT06718543: Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer

Recruiting
2
100
RoW
AK112 with SCRT and CapeOX, short-course radiotherapy, CapeOX, AK112 with SCRT
fan li
Rectal Cancer
10/26
10/27
NCT06686030: Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Recruiting
2
150
RoW
AK112 low dose, Ivonescimab, Chemotherapy, Olaparib, AK112 high dose
Akeso
Platinum-sensitive Ovarian Cancer
10/27
07/28
I-MAC, NCT06805617: A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Recruiting
2
35
US
Ivonescimab, SMT112, AK112
Glenn J. Hanna, Summit Therapeutics
Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
07/25
07/27
NCT06820762: Irinotecan Liposome(II) Combined with Ivonescimab As Second-line Treatment for Small Cell Lung Cancer : a Prospective, Single-arm, Multicenter Clinical Study

Not yet recruiting
2
40
RoW
irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity
The Second Affiliated Hospital of Dalian Medical University, Shengjing Hospital
SCLC
12/26
12/27
NCT06814158: Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

Not yet recruiting
2
57
RoW
Ivonescimab Combined With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamour Cell Cancer
07/26
12/26
NCT06848842: Ivonescimab Plus Chemotherapy in Patients with Initially Unresectable Colorectal Cancer Liver Metastases

Recruiting
2
40
RoW
Ivonescimab plus chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Liver Metastases
06/27
06/27
NCT06875076: Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

Recruiting
2
25
RoW
Ivonescimab Combined With Chemotherapy
The First Hospital of Jilin University
Pretreated Pleural Mesothelioma
01/28
12/29
NCT06944106: A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

Recruiting
2
30
RoW
AK112
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
04/26
03/27
AK112-IIT-016, NCT06919510: A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Not yet recruiting
2
90
NA
lvonescimab, CAPOX (oxaliplatin/capecitabine), radiotherapy, Surgery or watch&wait
Sun Yat-sen University, Akeso
Rectal Adenocarcinoma
06/26
12/28
NCT06925724: A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Recruiting
2
50
US
Ivonescimab
Memorial Sloan Kettering Cancer Center, Summit Therapeutics
Endometrial Cancer, Cervical Cancer
04/27
04/27
NCT06790212: Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

Not yet recruiting
2
168
NA
Ivonescimab, AK112, Oxaliplatin, Capecitabine
Sun Yat-sen University
Colon Cancer
08/27
06/28
NCT06936644: A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

Not yet recruiting
2
39
NA
IBI351+AK112, fulzerasib, ivonescimab
Shanghai Chest Hospital, Innovent Biologics, Inc., Akesobio
KRAS G12C Lung Cancer
04/27
03/28
NCT06993025: Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies

Not yet recruiting
2
30
RoW
Ivonescimab+chemotherapy, Ivonescimab+Liposomal Irinotecan + 5-FU/LV
Tianjin Medical University Cancer Institute and Hospital
Biliary Tract Cancer
04/26
04/27
WGOG-PAN 004, NCT06991491: Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer

Not yet recruiting
2
29
NA
GnP in combination with Ivonescimab and SBRT
West China Hospital
Pancreatic Cancer
06/26
09/26
NCT07009925: Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

Not yet recruiting
2
38
NA
Ivonescimab 20mg/kg intravenous every 3 weeks, paclitaxel polymeric micelles ≤300mg/㎡intravenous every 3 weeks, platinum intravenous every 3 weeks
Jiangsu Cancer Institute & Hospital
Squamous Cell Lung Cancer
05/27
05/28
AK112-IIT-201, NCT06977542: Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

Not yet recruiting
2
53
NA
Ivonescimab, AK112
Fudan University
TNBC, Triple Negative Breast Cancer
01/29
01/32
NCT06951646: ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Not yet recruiting
2
70
RoW
Ivonescimab plus docetaxel, Standard Treatment
Second Xiangya Hospital of Central South University, Akeso-Sino Pharma Co., Ltd., Nanjing Shihejiyin Technology, Inc.
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
07/28
06/30
Bi-MAPS, NCT06840834: Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

Not yet recruiting
2
38
Europe
Ivonescimab, SMT112
Intergroupe Francophone de Cancerologie Thoracique, Summit Therapeutics
Pleural Mesotheliomas
03/26
03/28
NCT06980077: Ivonescimab for the Treatment of Thymic Cancer

Not yet recruiting
2
25
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ivonescimab, AK 112, AK-112, AK112, Anti-PD-1/Anti-VEGF Bispecific Antibody AK112, Anti-PD-1/VEGF Bispecific Antibody AK112, PD-1/VEGF Bispecific Antibody AK112, SMT 112, SMT-112, SMT112, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Questionnaire Administration
Jonsson Comprehensive Cancer Center, Summit Therapeutics PLC
Thymus Carcinoma
06/27
06/28
SEVILLA, NCT06529718: Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Not yet recruiting
2
72
Europe
Ivonescimab, FOLFOX regimen
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, Summit Therapeutics
Biliary Tract Cancer
08/27
01/29
NCT07017673: Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Not yet recruiting
2
34
US
Ivonescimab, Carboplatin, Docetaxel
Cedars-Sinai Medical Center, Summit Therapeutics
TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
12/27
11/32
NCT07052253: A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Not yet recruiting
2
100
RoW
TT-00420 (tinengotinib), AK104, AK112
Akeso, TransThera Sciences (Nanjing), Inc.
Hepatocellular Carcinoma (HCC)
05/27
12/27
NCT07021950: AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Not yet recruiting
2
130
NA
AK112, Ivonescimab, FOLFIRI, Bevacizumab
Sun Yat-sen University
Colorectal Cancer, Ivonescimab
10/27
12/28
NCT06904300: Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Not yet recruiting
2
110
NA
AK112 + paclitaxel, Paclitaxel ± ramucirumab
Sun Yat-sen University
Gastric (Cardia, Body) Cancer
04/28
12/28
GRACIE, NCT06846346: Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Not yet recruiting
2
88
Europe
Ivonescimab, AK112, FOLFOX regimen, Oxaliplatin, folinic acid and 5-FU, Irinotecan, Campto, Paclitaxel, Taxol
UNICANCER, Summit Therapeutics
Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Advanced Gastric Adenocarcinoma
09/27
09/28
NCT06959550: Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Not yet recruiting
2
90
US
Ivonescimab
M.D. Anderson Cancer Center, Akesobio Australia Pty Ltd, Summit Therapeutics
Metastatic Colorectal Cancer
07/28
07/30
NCT06940518: Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Not yet recruiting
2
40
US
Ivonescimab
M.D. Anderson Cancer Center, Strategic Alliance, Summit Therapeutics Sub, Inc
Ivonescimab, Clear Cell Renal Carcinoma
01/28
01/30
NCT07038915: STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

Not yet recruiting
2
48
US
Tiragolumab, Ivonescimab
M.D. Anderson Cancer Center
Lung Squamous Cell Carcinoma, Anti-PD1/PDL1 Antibody
06/29
06/31
ChiCTR2400087910: Phase II Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Etoposide and Carboplatin for the First-line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Not yet recruiting
2
12
 
AK112+Etoposide+Carboplatin
Jilin Cancer Hospital; Jilin Cancer Hospital, Akeso Biopharma, Inc
Extensivedisease of small cell lung cancer, ES-SCLC
 
 
ChiCTR2400088480: Single-arm, open, exploratory study of ivonescimab combined with chemotherapy and SBRT in patients with advanced cholangiocarcinoma

Recruiting
2
35
 
Ivonescimab combined with chemotherapy and SBRT
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-funded
Locally advanced or metastatic BTC
 
 
ChiCTR2400085953: A single arm, open phase II clinical study of AK112 combined with GC regimen in the treatment of patients with potentially resectable biliary malignancies

Not yet recruiting
2
20
 
Received intravenous injection of Gemcitabine, cisplatin, and AK112
Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital, self-raised
Biliary Tract Cancer
 
 
ChiCTR2500100695: Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Recruiting
2
45
 
Short-term radiotherapy+evoximab +CAPOX regimen chemotherapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Optional topic
locally advanced rectal adenocarcinoma
 
 
ChiCTR2500095879: Conversion therapy of ivonescimab in combination with arterial Infusion chemotherapy for initial inoperable high rectal cancer: a single-arm, single-center clinical study

Not yet recruiting
2
20
 
Arterial Infusion chemotherapy plus ivonescimab
Tianjin Union Medical Center(The First Affiliated Hospital of Nankai University); Tianjin Union Medical Center(The First Affiliated Hospital of Nankai University), Raise independently
Rectal adenocarcinoma
 
 
ChiCTR2400090899: AK104 in combination with AK112 in an exploratory, multi-cohort stage II treatment of recurrent ovarian cancer study

Not yet recruiting
2
172
 
AK104（10mg/kg; AK112（20mg/kg， D1， Q3W） +AK104（10mg/kg， D8， Q6W）; AK112（20mg/kg， D1， Q3W） +AK104（10mg/kg， D8， Q6W） + （D1， Q3W）; AK112（20mg/kg
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Kangfang Pharmaceutical Co., LTD
Recurrent ovarian cancer
 
 
ChiCTR2500100475: A prospective, phase II, single-arm study evaluating the efficacy and safety of Ivonescimab (AK112) as induction and consolidation therapy for locally advanced/unresectable non-small cell lung cancer (NSCLC).

Not yet recruiting
2
30
 
Received 2 courses of induction therapy with SBRT and ivoneximab (AK112) in combination with platinum-doublet regimen, followed by standard concurrent chemoradiotherapy (chest radiotherapy Platinum-doublet chemotherapy), and finally ivoneximab (AK112) consolidation therapy for 1 year until progression, intolerable toxicity, death, withdrawal of informed consent, or 1 year of treatment, whichever occurs first
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Self-selected project (self-funded)
Non-small cell lung cancer (NSCLC)
 
 
ChiCTR2500096580: A prospective, open-label, single-arm, single-center phase II clinical study of Ivonescimab combined with chemotherapy in patients with advanced NSCLC and liver metastases.

Recruiting
2
30
 
Ivonescimab in combination with chemotherapy.
North China University of Science and Technology Affiliated Hospital; North China University of Science and Technology Affiliated Hospital, self-funded
Lung cancer
 
 
ChiCTR2500095834: A single-arm, open, single-center Phase II study of Ivonescimab (AK112) combined with chemotherapy in the treatment of platinum-resistant recurrent ovarian cancer

Not yet recruiting
2
40
 
AK112 combined with chemotherapy
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Akeso-Sino Pharma Co., Ltd.
ovarian cancer
 
 
ChiCTR2400086691: A single-arm, single-center, prospective phase II clinical trial of stereotactic body radiotherapy combined with AK112(PD-1 inhibitor and targeted therapy)in advanced hepatocellular carcinoma

Not yet recruiting
2
33
 
SBRT+AK112
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Shanghai Municipal Health Commission
Hepatocellular Carcinoma
 
 
ChiCTR2400089954: A Prospective, Multicenter Clinical Study of the Efficacy and Safety of First-Line Treatment with Ivonescimab in Combination with XELOX for Unresectable Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting
2
30
 
Ivonescimab in Combination with XELOX
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, self-funded
unresectable HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma
 
 
ChiCTR2400089410: A Single-Arm, Single-Center, Phase II Clinical Study of Neoadjuvant Treatment of Resectable EGFR-Sensitive Mutant Non-Small Cell Lung Cancer with Ivonescimab (Anti-PD-1 and VEGF Bispecific Antibody) Combination with Chemotherapy

Recruiting
2
25
 
Neoadjuvant treatment with ivonescimab (AK112) + platinum-containing two-drug chemotherapy
Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University, Study drug provided by Kangfang Sainuo Ltd.
NSCLC
 
 
ChiCTR2400090496: Ivonescimab (AK112) plus paclitaxel and carboplatin in frontline neoadjuvant therapy of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: a phase II trial

Recruiting
2
132
 
Ivonescimab 20mg/kg intravenously in 21-day cycle; Paclitaxel 175mg/m2 intravenously in 21-day cycle; Carboplatin AUC=5 intravenously in 21-day cycle
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Research funding from the sponsor
ovarian cancer
 
 
ChiCTR2500096723: Perioperative Kadonilimab+Ivonescimab combined with salvage resection in patients with recurrent, resectable head and neck squamous cell carcinoma: A phase II Clinical Trial

Not yet recruiting
2
32
 
Kadonilimab+Ivonescimab+salvage resection
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Horizontal funding
Recurrent head and neck squamous cell carcinoma
 
 
ChiCTR2500101645: Efficacy and safety of Ivonescimab combined with chemotherapy for neoadjuvant treatment of advanced ovarian cancer: a single-arm, open, multicenter clinical study.

Recruiting
2
50
 
The patients received 4 cycles of Ivonescimab combined with chemotherapy before surgery
Peking University Third Hospital; Peking University Third Hospital, Kangfang Pharmaceutical Co., LTD
ovarian cancer
 
 
AK112-102, NCT04597541: A Study of AK112 for Advanced Solid Tumors

Completed
1/2
59
RoW
AK112
Akeso
Solid Tumor, Adult
03/22
07/24
AK117-202, NCT05214482: A Study of AK112 in Advanced Malignant Tumors

Active, not recruiting
1/2
250
RoW
AK112, AK117, Chemotherapy
Akeso
Advanced Malignant Tumors
05/25
06/26
AK117-201, NCT05229497: A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Recruiting
1/2
114
RoW
AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil
Akeso
Advanced Malignant Tumors
02/23
02/24
AK112-202, NCT04900363: A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

Active, not recruiting
1/2
108
RoW
AK112
Akeso
Non-small Cell Lung Cancer
04/25
09/25
NCT05846867: A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

Recruiting
1/2
170
RoW
AK119, AK112, Oxaliplatin, Irinotecan, Calcium folinate, Fluorouracil
Akeso
Colorectal Cancer
05/26
08/26
NCT05689853: Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

Recruiting
1/2
87
RoW
AK119, AK112
Akeso
Solid Tumor, Adult
06/24
12/24
NCT06472895: A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma

Not yet recruiting
1/2
30
NA
AK112 monotherapy
Peking University Cancer Hospital & Institute
Renal Cell Carcinoma
12/25
12/27
NCT06530251: A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Not yet recruiting
1/2
280
RoW
AK112, Cadonilimab, AK127, AK130, Sintilimab Injection, Bevacizumab biosimilar
Akeso
Hepatocellular Carcinoma
06/26
09/28
Apple, NCT06196814: AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

Not yet recruiting
1/2
150
NA
PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
Hunan Province Tumor Hospital
Efficacy
03/26
02/27
NCT05636267: Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Recruiting
1/2
114
RoW
AK119, AK112, Pemetrexed, Carboplatin
Akeso
NSCLC
12/24
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
NCT06930573: A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

Recruiting
4
30
RoW
AK112
The First Affiliated Hospital of Zhengzhou University
HCC
05/26
12/27
AK112-RWS-IIT, ChiCTR2500096483: Real-world clinical studies of Ivonescimab in locally advanced or metastatic non-squamous NSCLC with EGFR-TKI treatment failure

Recruiting
4
30
 
Higher Education Mega Center Hospital of Guangdong Provincial Hospital of Chinese Medicine; Higher Education Mega Center Hospital of Guangdong Provincial Hospital of Chinese Medicine
Lung cancer
 
 
HARMONi, NCT06396065: Phase III Study of AK112 for NSCLC Patients

Active, not recruiting
3
420
Europe, Canada, US
AK112 Injection, Pemetrexed, Carboplatin, Placebo Injection
Summit Therapeutics, Akeso
Non-Squamous Non-small Cell Lung Cancer
12/25
12/25
HARMONi-2, NCT05499390: AK112 in Advanced Non-Small Cell Lung Cancer

Active, not recruiting
3
398
RoW
AK112, Pembrolizumab
Akeso
Advanced Non-small-cell Lung Cancer
01/24
12/25
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Not yet recruiting
3
682
RoW
AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin
Akeso
Biliary Tract Cancer
07/27
12/27
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
3
510
RoW
AK117 in combination with AK112, Placebo in combination with Pembrolizumab
Akeso
Head and Neck Squamous Cell Carcinoma
01/27
10/27
HARMONi-6, NCT05840016: AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Active, not recruiting
3
532
RoW
AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel
Akeso
Advanced Squamous Non Small Cell Lung Cancer
02/25
12/26
HARMONi-A, NCT05184712: Phase 3 Clinical Study of AK112 for NSCLC Patients

Active, not recruiting
3
322
RoW
Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection
Akeso, Akeso
Non-Squamous Non-small Cell Lung Cancer
06/24
11/25
HARMONi-BC1, NCT06767527: AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Not yet recruiting
3
416
RoW
AK112, Nab-paclitaxel, Placebo
Akeso
Triple-Negative Breast Cancer (TNBC)
12/26
12/28
HARMONi-7, NCT06767514: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Recruiting
3
780
US
Ivonescimab Injection, Pembrolizumab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
04/28
06/29
NCT06951503: A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Not yet recruiting
3
560
RoW
AK112, Oxaliplatin, Irinotecan, Leucovorin and 5-FU, Bevacizumab
Akeso
Colorectal Adenocarcinoma
01/27
01/29
NCT06953999: A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer

Not yet recruiting
3
999
RoW
Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine, Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine, Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine
Akeso
Pancreatic Cancer
05/27
05/28
AK112-311, NCT07010263: A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Not yet recruiting
3
480
RoW
AK112, Ivonescimab, Placebo
Akeso
Small Cell Lung Cancer
12/28
07/29
AK112-305, NCT06928389: Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Not yet recruiting
3
536
NA
Ivonescimab, docetaxel, AK112, docetaxel, Placebo, docetaxel
Akeso
Non-Small Cell Lung Cancer
05/27
06/30
HARMONi-3, NCT05899608: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting
3
1080
Europe, Canada, Japan, US, RoW
Ivonescimab Injection, Pembrolizumab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
12/27
12/28
ChiCTR2500102884: A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112（PD-1/VEGF Bispecific Antibody）Versus Placebo as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Not yet recruiting
3
480
 
AK112 injection placebo; AK112 Injection
Jilin Cancer Hospital; Jilin Cancer Hospital, Akeso-Sino Pharma Co., Ltd.
Limited-stage small cell lung cancer without progression after standard concurrent chemoradiotherapy
 
 
AK112-206, NCT05382442: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Recruiting
2
254
US, RoW
AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil
Akeso, Summit Therapeutics
Metastatic Colorectal Cancer
05/26
08/28
AK117-203, NCT05227664: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Recruiting
2
120
RoW
AK117, AK112, Nab paclitaxel, paclitaxel
Akeso
Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer
07/25
12/26
AK112-203, NCT04870177: Study of AK112 in the Treatment of Advanced Gynecological Tumors

Completed
2
53
RoW
AK112
Akeso
Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm, Endometrial Neoplasms
05/24
05/24
AK112-207, NCT05432492: A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Not yet recruiting
2
60
NA
AK112
Akeso
Hepatocellular Carcinoma
08/23
08/24
AK112-205, NCT05247684: AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Not yet recruiting
2
30
NA
AK112, Carboplatin, Cisplatin, Paclitaxel
Akeso
Resectable Non-small Cell Lung Cancer
08/23
01/25
AK104-IIT-042, NCT06196775: A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2
36
RoW
AK104+AK112
Harbin Medical University
Hepatocellular Carcinoma
01/26
01/27
AK112-201, NCT04736823: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

Recruiting
2
296
RoW
AK112, Pemetrexed, Paclitaxel, Carboplatin, Docetaxel
Akeso
NSCLC
07/25
12/26
NCT06375486: Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Recruiting
2
30
RoW
Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, HAIC
Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma
03/25
06/26
AK104-IIT-041, NCT06196697: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Recruiting
2
50
RoW
Cadonilimab, AK104, Ivonescimab, AK112, XELOX, oxaliplatin and capecitabine, SOX, oxaliplatin and Tegafur
Harbin Medical University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/27
03/27
NCT06391008: Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Not yet recruiting
2
44
NA
Stereotactic radiotherapy, Evoximab, AK112, Pemetrexed, Albumin Paclitaxel, Carboplatin
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
12/24
06/25
AK112-IIT-C-W-0001, NCT06444009: A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
2
90
RoW
Ivonescimab combined with TP, ITP, Cadonilimab combined with TP, CTP, Penpulimab combined with TP, PTP
Lei Liu
Head and Neck Squamous Cell Carcinoma
12/25
12/27
AK112-IIT-004, NCT06491472: Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Recruiting
2
36
RoW
Ivonescimab, AK112/SMT112, Gemcitabine, Nab paclitaxel, SBRT
Wuhan Union Hospital, China, Akesobio
Pancreatic Cancer
07/26
07/27
NCT06537011: AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
36
NA
AK112
Wuhan Union Hospital, China
Neoadjuvant Therapy of Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
07/27
07/28
NCT06637007: Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

Recruiting
2
30
RoW
Chidamide Tablets combined with AK112, AK112
Shanxi Province Cancer Hospital
Sarcoma,Soft Tissue, Sarcoma, Sarcoma of Bone
12/24
12/24
NCT06478043: A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

Not yet recruiting
2
54
RoW
ivonescimab, AK112, irinotecan liposome, Irinotecan liposome injection
Zhejiang Cancer Hospital
Extensive-stage Small-cell Lung Cancer
09/25
09/27
NCT06620796: A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer

Not yet recruiting
2
70
NA
Arm 1, AK112+AK104 group, second-line group, AK112+AK104+paclitaxel
Shanghai Pulmonary Hospital, Shanghai, China
SCLC, Extensive Stage
09/26
09/27
NCT06802666: Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Recruiting
2
45
RoW
short-course radiotherapy, SCRT, Ivonescimab, AK112, capecitabine, oxaliplatin, TME surgery
Wuhan Union Hospital, China
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
09/26
12/27
Miracle-03, NCT06593548: Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer

Not yet recruiting
2
36
RoW
Ivosidenib (AK112)
Fudan University
CRC, MSS, Metastatic Cancer
11/26
11/26
NCT06684873: A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)

Not yet recruiting
2
55
RoW
AK112 Injection
Sun Yat-sen University
NSCLC, Brain Metastasases
12/27
12/27
AK104-221, NCT06560112: An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Recruiting
2
172
RoW
AK104, Cadonilimab, AK112, Ivonescimab, Chemotherapy, Monotherapy Non-Platinum Chemotherapy chosen by the investigator
Akeso
Recurrent Ovarian Cancer
05/26
05/27
AK112-IIT-009, NCT06489197: AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

Recruiting
2
30
RoW
Ivonescimab combined with albumin paclitaxel and cisplatin
Tianjin Medical University Cancer Institute and Hospital
ESCC, Advanced Esophageal Squamous Cell Carcinoma
10/26
08/27
NCT06683846: Ivocizumab in the Treatment of Multiple Advanced Tumors

Recruiting
2
400
RoW
Ivocizumab
Fudan University
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular Epithelioid Cell Tumor, Malignant, Sarcoma, Urachal Cancer, Neuroendocrine Cancer, Basal Cell Carcinomas, Sarcomatoid Carcinoma, Penile Cancer, Adrenal Cortical Cancer, Germ Cell Cancer Metastatic, Non-Clear Cell Renal Cell Carcinoma, Prostate Cancers, Clear Cell Renal Cancer, Urothelial Carcinoma, Kidney Cancer, Rare Tumors
11/27
11/27
NCT06402435: SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer

Recruiting
2
50
RoW
Lvonescimab (AK112)
Hubei Cancer Hospital
Breast Cancer
08/26
09/27
NCT06401005: SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

Recruiting
2
51
RoW
Cadonilimab (AK104)
Hubei Cancer Hospital
Breast Cancer
08/26
09/27
NCT06567314: Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

Recruiting
2
24
US
Ivonescimab
M.D. Anderson Cancer Center, Summit Therapeutics
Cutaneous Squamous Cell Carcinoma
09/28
09/30
BALISTA, NCT06793332: BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

Recruiting
2
39
RoW
Ivonescimab Combined With TROP2 ADC, AK112 Combined With TROP2 ADC
Fudan University
Triple-Negative Breast Cancer (TNBC), Brain Metastases
01/26
01/27
iTHYM, NCT06750952: Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial

Not yet recruiting
2
24
NA
Ivonescimab Combined With Chemotherapy, AK112
Sun Yat-sen University
Relapsed or Metastatic Thymic Cancer, First-line Treatment
12/26
12/28
NCT06760520: Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer

Not yet recruiting
2
40
NA
Ivonescimab (SMT112 or AK112) Injection
The First Affiliated Hospital of Zhengzhou University
Locally Advanced Rectal Cancer
12/27
12/31
HX-AK112-01, NCT06769295: A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

Recruiting
2
28
RoW
AK112, Pemetrexed, Carboplatin/Cisplatin
Sichuan University
Lung Cancer, Non-Small Cell
12/26
12/27
HX-AK112-02, NCT06769971: Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Recruiting
2
80
RoW
Ivonescimab, Cadonilimab, Etoposide, Carboplatin
Sichuan University
Small Cell Lung Cancer
12/26
12/27
NCT06814067: Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
80
RoW
Pembrolizumab, Ivonescimab, Surgery, Adjuvant radiotherapy
Fudan University, Fujian Cancer Hospital
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
02/29
03/30
TRIUNITE-03, NCT06718543: Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer

Recruiting
2
100
RoW
AK112 with SCRT and CapeOX, short-course radiotherapy, CapeOX, AK112 with SCRT
fan li
Rectal Cancer
10/26
10/27
NCT06686030: Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Recruiting
2
150
RoW
AK112 low dose, Ivonescimab, Chemotherapy, Olaparib, AK112 high dose
Akeso
Platinum-sensitive Ovarian Cancer
10/27
07/28
I-MAC, NCT06805617: A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Recruiting
2
35
US
Ivonescimab, SMT112, AK112
Glenn J. Hanna, Summit Therapeutics
Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
07/25
07/27
NCT06820762: Irinotecan Liposome(II) Combined with Ivonescimab As Second-line Treatment for Small Cell Lung Cancer : a Prospective, Single-arm, Multicenter Clinical Study

Not yet recruiting
2
40
RoW
irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity
The Second Affiliated Hospital of Dalian Medical University, Shengjing Hospital
SCLC
12/26
12/27
NCT06814158: Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

Not yet recruiting
2
57
RoW
Ivonescimab Combined With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamour Cell Cancer
07/26
12/26
NCT06848842: Ivonescimab Plus Chemotherapy in Patients with Initially Unresectable Colorectal Cancer Liver Metastases

Recruiting
2
40
RoW
Ivonescimab plus chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Liver Metastases
06/27
06/27
NCT06875076: Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

Recruiting
2
25
RoW
Ivonescimab Combined With Chemotherapy
The First Hospital of Jilin University
Pretreated Pleural Mesothelioma
01/28
12/29
NCT06944106: A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

Recruiting
2
30
RoW
AK112
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
04/26
03/27
AK112-IIT-016, NCT06919510: A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Not yet recruiting
2
90
NA
lvonescimab, CAPOX (oxaliplatin/capecitabine), radiotherapy, Surgery or watch&wait
Sun Yat-sen University, Akeso
Rectal Adenocarcinoma
06/26
12/28
NCT06925724: A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Recruiting
2
50
US
Ivonescimab
Memorial Sloan Kettering Cancer Center, Summit Therapeutics
Endometrial Cancer, Cervical Cancer
04/27
04/27
NCT06790212: Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

Not yet recruiting
2
168
NA
Ivonescimab, AK112, Oxaliplatin, Capecitabine
Sun Yat-sen University
Colon Cancer
08/27
06/28
NCT06936644: A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

Not yet recruiting
2
39
NA
IBI351+AK112, fulzerasib, ivonescimab
Shanghai Chest Hospital, Innovent Biologics, Inc., Akesobio
KRAS G12C Lung Cancer
04/27
03/28
NCT06993025: Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies

Not yet recruiting
2
30
RoW
Ivonescimab+chemotherapy, Ivonescimab+Liposomal Irinotecan + 5-FU/LV
Tianjin Medical University Cancer Institute and Hospital
Biliary Tract Cancer
04/26
04/27
WGOG-PAN 004, NCT06991491: Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer

Not yet recruiting
2
29
NA
GnP in combination with Ivonescimab and SBRT
West China Hospital
Pancreatic Cancer
06/26
09/26
NCT07009925: Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

Not yet recruiting
2
38
NA
Ivonescimab 20mg/kg intravenous every 3 weeks, paclitaxel polymeric micelles ≤300mg/㎡intravenous every 3 weeks, platinum intravenous every 3 weeks
Jiangsu Cancer Institute & Hospital
Squamous Cell Lung Cancer
05/27
05/28
AK112-IIT-201, NCT06977542: Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

Not yet recruiting
2
53
NA
Ivonescimab, AK112
Fudan University
TNBC, Triple Negative Breast Cancer
01/29
01/32
NCT06951646: ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Not yet recruiting
2
70
RoW
Ivonescimab plus docetaxel, Standard Treatment
Second Xiangya Hospital of Central South University, Akeso-Sino Pharma Co., Ltd., Nanjing Shihejiyin Technology, Inc.
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
07/28
06/30
Bi-MAPS, NCT06840834: Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

Not yet recruiting
2
38
Europe
Ivonescimab, SMT112
Intergroupe Francophone de Cancerologie Thoracique, Summit Therapeutics
Pleural Mesotheliomas
03/26
03/28
NCT06980077: Ivonescimab for the Treatment of Thymic Cancer

Not yet recruiting
2
25
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ivonescimab, AK 112, AK-112, AK112, Anti-PD-1/Anti-VEGF Bispecific Antibody AK112, Anti-PD-1/VEGF Bispecific Antibody AK112, PD-1/VEGF Bispecific Antibody AK112, SMT 112, SMT-112, SMT112, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Questionnaire Administration
Jonsson Comprehensive Cancer Center, Summit Therapeutics PLC
Thymus Carcinoma
06/27
06/28
SEVILLA, NCT06529718: Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Not yet recruiting
2
72
Europe
Ivonescimab, FOLFOX regimen
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, Summit Therapeutics
Biliary Tract Cancer
08/27
01/29
NCT07017673: Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Not yet recruiting
2
34
US
Ivonescimab, Carboplatin, Docetaxel
Cedars-Sinai Medical Center, Summit Therapeutics
TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
12/27
11/32
NCT07052253: A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Not yet recruiting
2
100
RoW
TT-00420 (tinengotinib), AK104, AK112
Akeso, TransThera Sciences (Nanjing), Inc.
Hepatocellular Carcinoma (HCC)
05/27
12/27
NCT07021950: AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Not yet recruiting
2
130
NA
AK112, Ivonescimab, FOLFIRI, Bevacizumab
Sun Yat-sen University
Colorectal Cancer, Ivonescimab
10/27
12/28
NCT06904300: Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Not yet recruiting
2
110
NA
AK112 + paclitaxel, Paclitaxel ± ramucirumab
Sun Yat-sen University
Gastric (Cardia, Body) Cancer
04/28
12/28
GRACIE, NCT06846346: Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Not yet recruiting
2
88
Europe
Ivonescimab, AK112, FOLFOX regimen, Oxaliplatin, folinic acid and 5-FU, Irinotecan, Campto, Paclitaxel, Taxol
UNICANCER, Summit Therapeutics
Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Advanced Gastric Adenocarcinoma
09/27
09/28
NCT06959550: Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Not yet recruiting
2
90
US
Ivonescimab
M.D. Anderson Cancer Center, Akesobio Australia Pty Ltd, Summit Therapeutics
Metastatic Colorectal Cancer
07/28
07/30
NCT06940518: Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Not yet recruiting
2
40
US
Ivonescimab
M.D. Anderson Cancer Center, Strategic Alliance, Summit Therapeutics Sub, Inc
Ivonescimab, Clear Cell Renal Carcinoma
01/28
01/30
NCT07038915: STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

Not yet recruiting
2
48
US
Tiragolumab, Ivonescimab
M.D. Anderson Cancer Center
Lung Squamous Cell Carcinoma, Anti-PD1/PDL1 Antibody
06/29
06/31
ChiCTR2400087910: Phase II Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Etoposide and Carboplatin for the First-line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Not yet recruiting
2
12
 
AK112+Etoposide+Carboplatin
Jilin Cancer Hospital; Jilin Cancer Hospital, Akeso Biopharma, Inc
Extensivedisease of small cell lung cancer, ES-SCLC
 
 
ChiCTR2400088480: Single-arm, open, exploratory study of ivonescimab combined with chemotherapy and SBRT in patients with advanced cholangiocarcinoma

Recruiting
2
35
 
Ivonescimab combined with chemotherapy and SBRT
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-funded
Locally advanced or metastatic BTC
 
 
ChiCTR2400085953: A single arm, open phase II clinical study of AK112 combined with GC regimen in the treatment of patients with potentially resectable biliary malignancies

Not yet recruiting
2
20
 
Received intravenous injection of Gemcitabine, cisplatin, and AK112
Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital, self-raised
Biliary Tract Cancer
 
 
ChiCTR2500100695: Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Recruiting
2
45
 
Short-term radiotherapy+evoximab +CAPOX regimen chemotherapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Optional topic
locally advanced rectal adenocarcinoma
 
 
ChiCTR2500095879: Conversion therapy of ivonescimab in combination with arterial Infusion chemotherapy for initial inoperable high rectal cancer: a single-arm, single-center clinical study

Not yet recruiting
2
20
 
Arterial Infusion chemotherapy plus ivonescimab
Tianjin Union Medical Center(The First Affiliated Hospital of Nankai University); Tianjin Union Medical Center(The First Affiliated Hospital of Nankai University), Raise independently
Rectal adenocarcinoma
 
 
ChiCTR2400090899: AK104 in combination with AK112 in an exploratory, multi-cohort stage II treatment of recurrent ovarian cancer study

Not yet recruiting
2
172
 
AK104（10mg/kg; AK112（20mg/kg， D1， Q3W） +AK104（10mg/kg， D8， Q6W）; AK112（20mg/kg， D1， Q3W） +AK104（10mg/kg， D8， Q6W） + （D1， Q3W）; AK112（20mg/kg
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Kangfang Pharmaceutical Co., LTD
Recurrent ovarian cancer
 
 
ChiCTR2500100475: A prospective, phase II, single-arm study evaluating the efficacy and safety of Ivonescimab (AK112) as induction and consolidation therapy for locally advanced/unresectable non-small cell lung cancer (NSCLC).

Not yet recruiting
2
30
 
Received 2 courses of induction therapy with SBRT and ivoneximab (AK112) in combination with platinum-doublet regimen, followed by standard concurrent chemoradiotherapy (chest radiotherapy Platinum-doublet chemotherapy), and finally ivoneximab (AK112) consolidation therapy for 1 year until progression, intolerable toxicity, death, withdrawal of informed consent, or 1 year of treatment, whichever occurs first
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Self-selected project (self-funded)
Non-small cell lung cancer (NSCLC)
 
 
ChiCTR2500096580: A prospective, open-label, single-arm, single-center phase II clinical study of Ivonescimab combined with chemotherapy in patients with advanced NSCLC and liver metastases.

Recruiting
2
30
 
Ivonescimab in combination with chemotherapy.
North China University of Science and Technology Affiliated Hospital; North China University of Science and Technology Affiliated Hospital, self-funded
Lung cancer
 
 
ChiCTR2500095834: A single-arm, open, single-center Phase II study of Ivonescimab (AK112) combined with chemotherapy in the treatment of platinum-resistant recurrent ovarian cancer

Not yet recruiting
2
40
 
AK112 combined with chemotherapy
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Akeso-Sino Pharma Co., Ltd.
ovarian cancer
 
 
ChiCTR2400086691: A single-arm, single-center, prospective phase II clinical trial of stereotactic body radiotherapy combined with AK112(PD-1 inhibitor and targeted therapy)in advanced hepatocellular carcinoma

Not yet recruiting
2
33
 
SBRT+AK112
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Shanghai Municipal Health Commission
Hepatocellular Carcinoma
 
 
ChiCTR2400089954: A Prospective, Multicenter Clinical Study of the Efficacy and Safety of First-Line Treatment with Ivonescimab in Combination with XELOX for Unresectable Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting
2
30
 
Ivonescimab in Combination with XELOX
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, self-funded
unresectable HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma
 
 
ChiCTR2400089410: A Single-Arm, Single-Center, Phase II Clinical Study of Neoadjuvant Treatment of Resectable EGFR-Sensitive Mutant Non-Small Cell Lung Cancer with Ivonescimab (Anti-PD-1 and VEGF Bispecific Antibody) Combination with Chemotherapy

Recruiting
2
25
 
Neoadjuvant treatment with ivonescimab (AK112) + platinum-containing two-drug chemotherapy
Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University, Study drug provided by Kangfang Sainuo Ltd.
NSCLC
 
 
ChiCTR2400090496: Ivonescimab (AK112) plus paclitaxel and carboplatin in frontline neoadjuvant therapy of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: a phase II trial

Recruiting
2
132
 
Ivonescimab 20mg/kg intravenously in 21-day cycle; Paclitaxel 175mg/m2 intravenously in 21-day cycle; Carboplatin AUC=5 intravenously in 21-day cycle
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Research funding from the sponsor
ovarian cancer
 
 
ChiCTR2500096723: Perioperative Kadonilimab+Ivonescimab combined with salvage resection in patients with recurrent, resectable head and neck squamous cell carcinoma: A phase II Clinical Trial

Not yet recruiting
2
32
 
Kadonilimab+Ivonescimab+salvage resection
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Horizontal funding
Recurrent head and neck squamous cell carcinoma
 
 
ChiCTR2500101645: Efficacy and safety of Ivonescimab combined with chemotherapy for neoadjuvant treatment of advanced ovarian cancer: a single-arm, open, multicenter clinical study.

Recruiting
2
50
 
The patients received 4 cycles of Ivonescimab combined with chemotherapy before surgery
Peking University Third Hospital; Peking University Third Hospital, Kangfang Pharmaceutical Co., LTD
ovarian cancer
 
 
AK112-102, NCT04597541: A Study of AK112 for Advanced Solid Tumors

Completed
1/2
59
RoW
AK112
Akeso
Solid Tumor, Adult
03/22
07/24
AK117-202, NCT05214482: A Study of AK112 in Advanced Malignant Tumors

Active, not recruiting
1/2
250
RoW
AK112, AK117, Chemotherapy
Akeso
Advanced Malignant Tumors
05/25
06/26
AK117-201, NCT05229497: A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Recruiting
1/2
114
RoW
AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil
Akeso
Advanced Malignant Tumors
02/23
02/24
AK112-202, NCT04900363: A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

Active, not recruiting
1/2
108
RoW
AK112
Akeso
Non-small Cell Lung Cancer
04/25
09/25
NCT05846867: A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

Recruiting
1/2
170
RoW
AK119, AK112, Oxaliplatin, Irinotecan, Calcium folinate, Fluorouracil
Akeso
Colorectal Cancer
05/26
08/26
NCT05689853: Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

Recruiting
1/2
87
RoW
AK119, AK112
Akeso
Solid Tumor, Adult
06/24
12/24
NCT06472895: A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma

Not yet recruiting
1/2
30
NA
AK112 monotherapy
Peking University Cancer Hospital & Institute
Renal Cell Carcinoma
12/25
12/27
NCT06530251: A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Not yet recruiting
1/2
280
RoW
AK112, Cadonilimab, AK127, AK130, Sintilimab Injection, Bevacizumab biosimilar
Akeso
Hepatocellular Carcinoma
06/26
09/28
Apple, NCT06196814: AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

Not yet recruiting
1/2
150
NA
PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
Hunan Province Tumor Hospital
Efficacy
03/26
02/27
NCT05636267: Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Recruiting
1/2
114
RoW
AK119, AK112, Pemetrexed, Carboplatin
Akeso
NSCLC
12/24
03/25
 

Download Options